Join the club for FREE to access the whole archive and other member benefits.

New cancer drug shrinks tumour in phase 1 trial

Indeed a new precision approach sparing healthy cells

23-Jun-2020

Key points from article :

A drug that could stop cancer cells repairing themselves has shown early signs of working.

More than half of the 40 patients given berzosertib had the growth of their tumours halted.

The study involved those with very advanced tumours, for whom no other treatment had worked.

It was even more effective when given alongside chemotherapy.

It is the first to be trialled of a new family of treatments, blocking a protein in DNA repair.

Blocking this protein prevents cancers from mending damage to their cells.

A patient's tumours shrunk after receiving treatment for six years now.

Berzosertib is able to target tumour cells without affecting other healthy cells

In the future, these drugs could be used to "boost the effect of treatments like chemotherapy".

If used alone this could provide a less aggressive option than chemotherapy.

The next phase of the trial is already underway.

Research by Institute of Cancer Research (ICR) and the Royal Marsden NHS Trust

Mentioned in this article:

Click on resource name for more details.

Chris Lord

Professor of cancer genomics at the ICR

Darius Widera

Associate Professor, University of Reading

Royal Marsden NHS Foundation Trust

Hospital dedicated to cancer diagnosis, treatment, research and education.

The Institute of Cancer Research (ICR)

One of the world’s most influential cancer research organizations

University of Reading

Public university in Reading, England

Topics mentioned on this page:
Cancer